{"denoms":[{"counts":[{"groupId":"BG000","value":"25"}],"units":"Participants"}],"groups":[{"description":"Participants received rituximab as an intravenous (IV) infusion of 375 milligrams per meter squared (mg/m\\^2) once a week on Days 1, 8, 15 and 22 during the Remission Induction Phase (Day 1 (baseline) to Month 6) and were followed for a minimum of 18 months (maximum 4.5yrs) during the Follow-up Phase until the Common-closeout (CCO))","id":"BG000","title":"Rituximab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2.9","value":"13.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Multiple"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"}]}